Bimekizumab efficacy in subgroups defined by prior systemic treatment in patients with moderate to severe plaque psoriasis

被引：0

作者：

Rosmarin, David ^{[1
]}

Lebwohl, Mark ^{[2
]}

Feldman, Steven R. ^{[3
]}

Staubach-Renz, Petra ^{[4
]}

Davis, Leah ^{[5
]}

Wixted, Krista ^{[5
]}

Madden, Cynthia ^{[5
]}

Gomez, Natalie Nunez ^{[6
]}

Pinter, Andreas ^{[7
]}

机构：

[1] Tufts Med Ctr, Dept Dermatol, Boston, MA USA

[2] Icahn Sch Med Mt Sinai, New York, NY USA

[3] Wake Forest Sch Med, Dept Dermatol, Winston Salem, NC USA

[4] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Dermatol, Mainz, Germany

[5] UCB Pharma, Raleigh, NC USA

[6] UCB Pharma, Brussels, Belgium

[7] Univ Hosp Frankfurt, Frankfurt, Germany

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2022年 / 87卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

34320

引用

页码：AB146 / AB146

页数：1

共 50 条

[21] EFFICACY OF TILDRAKIZUMAB IN MODERATE TO SEVERE PSORIASIS PATIENTS WITH PRIOR EXPOSURE TO APREMILAST
Gordon, Kenneth
Reich, Kristian
Pariser, David
Menter, Alan
Tyring, Stephen
Sofen, Howard
Rozzo, Stephen
Parno, Jeffrey
Li, Qing
La Rosa, Carmen
[J]. ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 29 - 30
[22] Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis
Armstrong, April
Fahrbach, Kyle
Leonardi, Craig
Augustin, Matthias
Neupane, Binod
Kazmierska, Paulina
Betts, Marissa
Freitag, Andreas
Kiri, Sandeep
Taieb, Vanessa
Slim, Mahmoud
Gomez, Natalie Nunez
Warren, Richard B.
[J]. DERMATOLOGY AND THERAPY, 2022, 12 (08) : 1777 - 1792
[23] Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis
Li, Wendy
Ghamrawi, Rima
Haidari, Wasim
Feldman, Steven R.
[J]. ANNALS OF PHARMACOTHERAPY, 2020, 54 (04) : 380 - 387
[24] Treatment of moderate-to-severe plaque psoriasis
Salgo, R.
Thaci, D.
[J]. GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2009, 144 (06): : 701 - 711
[25] Efalizumab for the treatment of moderate to severe plaque psoriasis
Jordan, JK
[J]. ANNALS OF PHARMACOTHERAPY, 2005, 39 (09) : 1476 - 1482
[26] Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: Results from the BE RADIANT phase 3b trial
Eyerich, Kilian
Gottlieb, Alice B.
Piaserico, Stefano
Beissert, Stefan
Gooderham, Melinda
Kirby, Brian
Tilt, Nicola
Madden, Cynthia
Wiegratz, Susanne
de Cuyper, Dirk
Elewski, Boni
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB22 - AB22
[27] Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis
April Armstrong
Kyle Fahrbach
Craig Leonardi
Matthias Augustin
Binod Neupane
Paulina Kazmierska
Marissa Betts
Andreas Freitag
Sandeep Kiri
Vanessa Taieb
Mahmoud Slim
Natalie Nunez Gomez
Richard B. Warren
[J]. Dermatology and Therapy, 2022, 12 : 1777 - 1792
[28] Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial
Eyerich, Kilian
Gottlieb, Alice B.
Piaserico, Stefano
Beissert, Stefan
Gooderham, Melinda
Kirby, Brian
Tilt, Nicola
Madden, Cynthia
Wiegratz, Susanne
de Cuyper, Dirk
Merola, Joseph F.
Elewski, Boni
[J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4467 - 4469
[29] Efficacy and safety of etanercept in moderate to severe plaque psoriasis
Tunca, M.
Koc, E.
Akar, A.
Kurumlu, Z.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2007, 21 : 53 - 53
[30] Efficacy and safety of secukinumab in moderate to severe plaque psoriasis
Aparicio Rubio, Celia
Monteagudo Santolaya, Emilio
Cornejo Uixeda, Silvia
Prieto Castello, Manuel
Antonino de la Camara, Gonzalo
Quintana Vergara, Belen
Sanchez Alcaraz, Agustin
[J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (01) : 299 - 299

← 1 2 3 4 5 →